Heterogeneity of electrically evoked dopamine release and reuptake in substantia nigra, ventral tegmental area, and striatum.

Somatodendritic dopamine (DA) released in substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) may mediate extrasynaptic neuronal signaling. The concentration of extracellular DA ([DA]o) attained during somatodendritic activation will be governed by the density of release sites and properties of DA uptake. We evaluated these factors in SNc, VTA, and dorsal striatum with carbon-fiber microelectrodes and fast-scan cyclic voltammetry to monitor [DA]o during local electrical stimulation (10 Hz, 5 s) in guinea pig brain slices. Stimulated DA efflux was site specific, with significantly higher [DA]o in caudal (0.48 +/- 0.03 microM, mean +/- SE) than rostral SNc (0.16 +/- 0.01 microM), averaged over their mediolateral extents, and higher [DA]o in VTA (0.74 +/- 0.07 microM) than in medial (0.43 +/- 0.04 microM) or lateral SNc (0.29 +/- 0.05 microM), averaged rostrocaudally. Throughout SNc, evoked [DA]o correlated positively (r = 0.91) with the density of tyrosine-hydroxylase-immunoreactive cells. Modulation of evoked [DA]o by uptake was also site specific. The selective DA uptake inhibitor GBR 12909 significantly increased evoked [DA]o in caudal SNc (to 185 +/- 27%) and striatum (408 +/- 24%), but had no effect in rostral SNc or VTA. Conversely, the norepinephrine (NE) uptake inhibitor desipramine did not alter stimulated [DA]o in caudal SNc or striatum, but caused significant enhancement in rostral SNc (196 +/- 17%) and VTA (126 +/- 12%). Paroxetine, a selective 5-hydroxytryptamine uptake inhibitor had little effect in any region tested. Site-specific sensitivity to desipramine mandated evaluation of dopamine-beta-hydroxylase immunoreactivity (D beta H-ir) in midbrain. The density of filaments positive for D beta H-ir was greater in rostral SNc and VTA than in caudal SNc, suggesting DA clearance via the NE transporter in these regions. Importantly, D beta H-ir was most dense in sections rostral to SNc where no catecholamine signal was detected and no enhancement was observed with desipramine, indicating a lack of NE contribution to evoked release in any region examined. Taken together, these data confirmed that evoked somatodendritic [DA]o depends on DA cell density and on local uptake properties. Uptake was less efficient in SNc and VTA than in striatum. Moreover, enhancement of stimulated [DA]o by GBR 12909 demonstrated that evoked release from dendrites is not via reversal of the DA transporter. Lastly, the heterogeneous patterns of DA uptake within SNc and VTA were consistent with the pattern of degeneration in Parkinson's disease; less vulnerable DA cells, e.g., those in VTA, have less DA uptake than the more vulnerable cells of caudal SNc.

[1]  A. M. Johnson,et al.  The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. , 1992, The Journal of clinical psychiatry.

[2]  R. Roth,et al.  Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons , 1984, Neuroscience.

[3]  J. Weissman,et al.  Volume Transmission in the Brain , 1992, Neurology.

[4]  J. Millar,et al.  Application of fast cyclic voltammetry to measurement of electrically evoked dopamine overflow from brain slices in vitro , 1990, Journal of Neuroscience Methods.

[5]  A. Graybiel,et al.  Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervation of striosomes and extrastriosomal matrix , 1987, Neuroscience.

[6]  Charles Nicholson,et al.  Diffusion and Ion Shifts in the Brain Extracellular Microenvironment and Their Relevance for Voltammetric Measurements , 1995 .

[7]  E. Abercrombie,et al.  Biochemistry of Somatodendritic Dopamine Release in Substantia Nigra: An In Vivo Comparison with Striatal Dopamine Release , 1995, Journal of neurochemistry.

[8]  G. Uhl,et al.  Dopamine transporter mRNA: dense expression in ventral midbrain neurons. , 1992, Brain research. Molecular brain research.

[9]  D. German,et al.  Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three‐dimensional reconstruction in the rat , 1993, The Journal of comparative neurology.

[10]  L. Pozzi,et al.  Evidence that Extracellular Concentrations of Dopamine Are Regulated by Noradrenergic Neurons in the Frontal Cortex of Rats , 1994, Journal of neurochemistry.

[11]  P. Groves,et al.  The substantia nigra of the rat: A golgi study , 1977, The Journal of comparative neurology.

[12]  R. Mark Wightman,et al.  Interference by pH and Ca2+ ions during measurements of catecholamine release in slices of rat amygdala with fast-scan cyclic voltammetry , 1994, Journal of Neuroscience Methods.

[13]  H. Nissbrandt,et al.  Reserpine-insensitive dopamine release in the substantia nigra? , 1991, Brain Research.

[14]  P. Garris,et al.  Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  W. Smeets,et al.  Distribution of noradrenaline immunoreactivity in the forebrain and midbrain of the lizard Gekko gecko , 1989, The Journal of comparative neurology.

[16]  L. Manzino,et al.  Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. , 1984, European journal of pharmacology.

[17]  C. Nicholson Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. , 1995, Biophysical journal.

[18]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[19]  J. Fallon,et al.  Catecholamine innervation of the basal forebrain IV. Topography of the dopamine projection to the basal forebrain and neostriatum , 1978, The Journal of comparative neurology.

[20]  John T. Williams,et al.  Dopamine D1 receptors facilitate transmitter release , 1993, Nature.

[21]  S. Greenfield,et al.  Topographic heterogeneity of substantia nigra neurons: Diversity in intrinsic membrane properties and synaptic inputs , 1993, Neuroscience.

[22]  Johnson Am,et al.  The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. , 1992 .

[23]  M. Sanghera,et al.  Low dopamine transporter mRNA levels in midbrain regions containing calbindin. , 1994, Neuroreport.

[24]  F I Carroll,et al.  In vivo binding of [125I] RTI‐55 to dopamine transporters: Pharmacology and regional distribution with autoradiography , 1992, Synapse.

[25]  C. Gerfen,et al.  The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[26]  J. Glowinski,et al.  Release of dopamine in vivo from cat substantia nigra , 1977, Nature.

[27]  J. Walters,et al.  Endogenous dopamine can modulate inhibition of substantia nigra pars reticulata neurons elicited by GABA iontophoresis or striatal stimulation , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  D. Robertson,et al.  Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites , 1993, Neuroscience Letters.

[29]  G. Chiara,et al.  Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex: Evidence that Dopamine Is Taken up In Vivo by Noradrenergic Terminals , 1990, Journal of neurochemistry.

[30]  V. M. Pickel,et al.  The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Gerfen,et al.  The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  A. Reyes,et al.  Dopamine transporter mediated release of dopamine: Role of chloride , 1994, Journal of neuroscience research.

[33]  W. Schultz,et al.  The catecholamine uptake inhibitor nomifensine depresses impulse activity of dopamine neurons in mouse substantia nigra , 1987, Neuroscience Letters.

[34]  B. Ghetti,et al.  Is there a significant somatodendritic uptake of dopamine in the substantia nigra? Evidence from the weaver mutant mouse , 1993, Neurochemistry International.

[35]  Distribution of dopamine-immunoreactive cell bodies in the guinea-pig brain. , 1990, Journal of chemical neuroanatomy.

[36]  J. Fallon,et al.  Substantia nigra dopamine neurons: separate populations project to neostriatum and allocortex , 1978, Neuroscience Letters.

[37]  C. Nicholson,et al.  Measurement of nanomolar dopamine diffusion using low-noise perfluorinated ionomer coated carbon fiber microelectrodes and high-speed cyclic voltammetry. , 1989, Analytical chemistry.

[38]  P. H. Andersen The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action , 1989 .

[39]  S. Hersch,et al.  The dopamine transporter: immunochemical characterization and localization in brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  S. Greenfield The significance of dendritic release of transmitter and protein in the substantia nigra , 1985, Neurochemistry International.

[41]  G. Uhl,et al.  Dopamine transporter: expression in Xenopus oocytes. , 1991, Brain research. Molecular brain research.

[42]  S. Greenfield,et al.  Sub-populations of pars compacta neurons in the substantia nigra: The significance of qualitatively and quantitatively distinct conductances , 1992, Neuroscience.

[43]  M. Zigmond,et al.  High glutamate concentrations evoke Ca(++)-independent dopamine release from striatal slices: a possible role of reverse dopamine transport. , 1991, The Journal of pharmacology and experimental therapeutics.

[44]  Y. Hurd,et al.  The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons , 1994, Neuroscience.

[45]  E. Richfield Quantitative autoradiography of the dopamine uptake complex in rat brain using [3H]GBR 12935: binding characteristics , 1991, Brain Research.

[46]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[47]  K. Neve,et al.  Release of dopamine via the human transporter. , 1994, Molecular pharmacology.

[48]  H. Nissbrandt,et al.  Effects of drugs interfering with sodium channels and calcium channels on the release of endogenous dopamine from superfused substantia nigra slices , 1997, Synapse.

[49]  N. Mercuri,et al.  Actions of cocaine on rat dopaminergic neurones in vitro , 1990, British journal of pharmacology.

[50]  D. Sulzer,et al.  Amphetamine and Other Weak Bases Act to Promote Reverse Transport of Dopamine in Ventral Midbrain Neurons , 1993, Journal of neurochemistry.

[51]  M. Kuhar,et al.  The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[52]  M. Raiteri,et al.  Carrier-mediated release of neurotransmitters , 1993, Trends in Neurosciences.

[53]  C. Marsden,et al.  Evidence that [3H]Dopamine Is Taken Up and Released from Nondopaminergic Nerve Terminals in the Rat Substantia Nigra In Vitro , 1985, Journal of neurochemistry.

[54]  P. Mcgeer,et al.  Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K , 1990, Brain Research.

[55]  O. Lindvall,et al.  Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals , 1975, Brain Research.

[56]  G. Paxinos,et al.  Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography , 1991, The Journal of comparative neurology.

[57]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Kalivas,et al.  A Comparison of Axonal and Somatodendritic Dopamine Release Using In Vivo Dialysis , 1991, Journal of neurochemistry.

[59]  C. Nicholson,et al.  Diffusion in the slice microenvironment and implications for physiological studies. , 1983, Federation proceedings.

[60]  M. Caron,et al.  Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[61]  T. Jessell,et al.  Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.

[62]  W. Annaert,et al.  Immunocytochemical demonstration of dopamine-beta-hydroxylase and cytochrome B561 on the axonal reticulum in bovine sympathetic neurons. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[63]  G. Uhl,et al.  Dopamine transporter immunoreactivity in rat brain , 1995, The Journal of comparative neurology.

[64]  A. D. Smith,et al.  Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy , 1995, Neuroscience.

[65]  Y. Agid,et al.  Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. , 1994, Brain research. Molecular brain research.

[66]  Y. Hishikawa,et al.  Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[67]  W. Gibb,et al.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[68]  P. Calabresi,et al.  Dopamine uptake inhibition potentiates the effects of l-DOPA on rat substantia nigra zona compacta neurons , 1991, Neuroscience Letters.

[69]  D. German,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost? , 1988, Neuroscience.

[70]  E. Sundström,et al.  Uptake inhibition protects nigro-striatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenylpyridine (MPP+) in mice. , 1986, European journal of pharmacology.

[71]  S. Cragg,et al.  Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. , 1997, Journal of neurophysiology.

[72]  W. Smeets,et al.  Distribution of serotonin immunoreactivity in the forebrain and midbrain of the lizard Gekko gecko , 1988, The Journal of comparative neurology.

[73]  S J Young,et al.  Self-inhibition by dopaminergic neurons , 1975, Science.

[74]  C. Gerfen,et al.  The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[75]  B. K. Krueger,et al.  Kinetics and Block of Dopamine Uptake in Synaptosomes from Rat Caudate Nucleus , 1990, Journal of neurochemistry.

[76]  P. Calabresi,et al.  The mechanism of amphetamine‐induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro , 1989, British journal of pharmacology.

[77]  C. Sotelo,et al.  Dopaminergic dendrites in the pars reticulata of the rat substantia nigra and their striatal input. combined immunocytochemical localization of tyrosine hydroxylase and anterograde degeneration , 1981, Neuroscience.